A multifunctional visualized nanodrug delivery platform integrating chemotherapy, phototherapy and gas therapy and its application
Through the integration of chemotherapy, phototherapy and gas treatment based on MIL-101 metal organic framework, the problems of poor solubility and insufficient targeting in the prior art are solved, and an efficient multifunctional visual nanodrug delivery platform is realized, which significantly inhibits Tumor growth and controls cancer progression.
Patent Information
- Application Number
- CN202410235649.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-01
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-03-01
AI Technical Summary
The prior art is difficult to effectively integrate chemotherapy, phototherapy and gas therapy in cancer treatment, especially due to poor solubility, insufficient targeting and different metabolic distribution of drugs, resulting in limited therapeutic effects, especially for cancers with high tumor burden and chemotherapy resistance. The case is not effective.
Using nanomaterials based on MIL-101 metal organic framework, integrating chemotherapeutic drug lonidamine, phototherapeutic agent IR780 and hydrogen sulfide donor, loading the drug on the surface and micropores of the nanomaterial through electrostatic action and covalent bonding, achieving multiple Functional visualization of nanodrug delivery platform, combining chemotherapy, photodynamic therapy and gas therapy, enhances targeted and cellular oxidative stress response to mitochondria.
It realizes efficient targeting and visual monitoring of drugs, enhances the damage effect on tumor cells, improves the solubility and biocompatibility of drugs, and significantly inhibits tumor growth under synergistic action and controls cancer progression.
Smart Images

Figure CN118059262B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to a multifunctional visualized nano drug delivery platform integrating chemotherapy, phototherapy and gas therapy and applications thereof. Background Art
[0002] Cancer remains a thorny problem that threatens human health worldwide. Its occurrence and development is a complex process. At present, people have made many achievements in exploring methods to treat cancer. Chemotherapy, phototherapy, chemodynamic therapy, radiotherapy and immunotherapy have been proven to be effective in clinical practice.
[0003] Chemotherapy has been widely studied as a major treatment modality other than surgery. In the past two decades, new therapies have continued to emerge, but chemotherapy remains irreplaceable in cancer treatment. Lonidamine is a derivative of indazole-3-carboxylic acid, which is known to mainly affect cellular energy metabolism, impair mitochondrial function, and inhibit glycolysis in tumor cells. It has been used to treat various tumors, including breast cancer, prostate cancer, lung cancer, and brain tumors, and is increasingly being studied and applied due to its broad anticancer spectrum and few side effects. Recent research focuses on overcoming the problems of poor solubility and off-target toxicity of lonidamine.
[0004] Phototherapy is an emerging treatment strategy in recent years and an important means of comprehensive cancer treatment. Photosensitizers are the key to phototherapy. After being stimulated by light, they can quickly increase the temperature of surrounding tissues, causing temporary or permanent inactivation of intracellular proteins, while catalyzing the production of reactive oxygen species (ROS), triggering cellular oxidative stress reactions. Some photosensitizers can also emit fluorescent signals, which are of great significance for visual treatment in clinical practice. In recent years, phototherapy has received increasing attention due to its non-invasive, low side effects, and high patient acceptance.
[0005] Hydrogen sulfide has been confirmed to be the third intracellular gaseous signaling molecule alongside nitric oxide and carbon monoxide. It is closely related to a variety of physiological and pathological processes and has good therapeutic potential. Similar to nitric oxide and carbon monoxide, it exhibits biphasic pharmacological properties in cancer treatment, that is, at low concentrations, it exhibits a pro-cancer effect; at higher concentrations, it exhibits an anti-cancer effect. Therefore, before applying hydrogen sulfide to treat cancer, how to continuously release high concentrations of hydrogen sulfide in the body is a difficult problem that needs to be solved urgently. In addition, although high concentrations of hydrogen sulfide have been shown to have significant anti-tumor activity in vivo, its toxicity is still much lower than that of certain specialized chemotherapy drugs. Therefore, the use of gaseous transmitters such as hydrogen sulfide should be combined with other anti-tumor methods while inhibiting tumor proliferation.
[0006] Single cancer treatment methods have very limited effects on the treatment of complex and heterogeneous tumors, especially for cancer cases with high tumor burden, chemotherapy resistance and advanced disease. As the tumor microenvironment (TME) has been paid more attention, more and more mechanisms of cancer occurrence have been revealed, and cocktail therapy combining multiple treatment methods has received widespread attention and has become an important component of cancer treatment programs. The biggest challenge facing combination therapy is that drugs from different therapies differ in physicochemical properties, pharmacokinetics and biodistribution patterns, making them difficult to integrate. Metal organic framework (MOFs) materials are considered to be able to overcome the above difficulties and are the most promising combination therapy drug delivery platform for clinical use. The present invention intends to integrate multiple treatment methods and develop a multifunctional visualized nanodrug delivery platform to achieve the purpose of controlling cancer while visually monitoring tumor development and treatment process while inhibiting tumor growth. Summary of the invention
[0007] The purpose of the present invention is to provide a multifunctional visualized nano drug delivery platform integrating chemotherapy, phototherapy and gas therapy and its application to solve the problems existing in the above-mentioned prior art. The multifunctional visualized nano drug delivery platform uses nanomaterials based on MIL-101 metal organic framework, integrates multiple therapies including chemotherapy, phototherapy and gas therapy, and utilizes drug fluorescence to visualize and monitor tumor development and treatment process, while inhibiting tumor growth to achieve the purpose of controlling cancer.
[0008] To achieve the above object, the present invention provides the following solutions:
[0009] The present invention provides a multifunctional visualized nano drug delivery platform, comprising a metal nano material, an organic drug molecule and a hydrogen sulfide donor, wherein the organic drug molecule is loaded on the surface and micropores of the metal nano material, and the hydrogen sulfide donor is modified on the surface of the metal nano material.
[0010] Furthermore, the metal nanomaterial is composed of a metal coordination center trivalent Fe coordinated with a ligand 2-aminoterephthalic acid, and the metal nanomaterial is in a regular octahedron.
[0011] Furthermore, the organic drug molecule is a dimer composed of a tumor drug molecule and a tumor targeting molecule.
[0012] Furthermore, the tumor drug molecule is lonidamine, the tumor targeting molecule is IR780, and the structural formula of the dimer is as follows:
[0013]
[0014] Furthermore, the organic drug molecules are loaded on the surface and micropores of the metal nanomaterial through electrostatic interaction.
[0015] Furthermore, the hydrogen sulfide donor is 5-(4-hydroxyphenyl)-3H-1,2-disulfide-3-thione.
[0016] Furthermore, the hydrogen sulfide donor is modified on the surface of the metal nanomaterial via covalent bonds.
[0017] The present invention also provides the use of the multifunctional visualized nano drug delivery platform in the preparation of tumor therapeutic drugs.
[0018] The present invention also provides a tumor therapeutic drug, comprising the multifunctional visualized nano drug delivery platform.
[0019] Furthermore, the drug also includes pharmaceutically acceptable excipients.
[0020] The present invention discloses the following technical effects:
[0021] (1) IR780 is a positively charged cyanine dye with inherent targeting ability to mitochondria. It forms a dimeric prodrug with lonidamine through a disulfide bond, which can target lonidamine to mitochondria, enhance the damage and inhibitory effects of lonidamine on mitochondria, and enhance the efficacy of lonidamine.
[0022] (2) Under laser irradiation, IR780 can rapidly increase the temperature of tumor tissue, leading to cell inactivation, while generating bright fluorescence signals that can be used to monitor the progress of cancer treatment.
[0023] (3) At higher temperatures, IR780-mediated photodynamic therapy (PDT) and iron-mediated chemodynamic therapy (CDT) produce a synergistic effect, rapidly inducing cellular oxidative stress.
[0024] (4) Hydrogen sulfide donors continuously release high concentrations of hydrogen sulfide in cells, inhibiting cancer-promoting signaling pathways.
[0025] (5) The nano drug delivery platform provided by the present invention improves the problems of poor solubility of each component, lack of targeting, and large differences in metabolic distribution, and cleverly integrates various combined treatment methods together.
[0026] (6) The nano drug delivery platform provided by the present invention has good biocompatibility and safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0028] Figure 1 Schematic diagram of the synthesis route of organic compound ISL;
[0029] Figure 2 Schematic diagram of the preparation process of the nano drug delivery platform;
[0030] Figure 3 The figures are scanning electron microscope (SEM) and transmission electron microscope (TEM) images of the nano drug delivery platform; A is the SEM image; B is the TEM image;
[0031] Figure 4 It is the adsorption-desorption isotherm diagram of the nano drug delivery platform;
[0032] Figure 5 This is the pore size distribution diagram of the nano drug delivery platform;
[0033] Figure 6 This is the X-ray energy dispersion spectrum of the nano drug delivery platform;
[0034] Figure 7 Results of blood sample analysis of tumor-bearing nude mice; A is a statistical graph of total protein (TP), urea (UREA) and glucose (GLU) in the blood; B is a statistical graph of creatinine (CREA), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the blood; C is a statistical graph of alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and creatine kinase (CK) in the blood;
[0035] Figure 8 H&E staining of the main organs and tumor tissues of tumor-bearing nude mice;
[0036] Fig. 9 This is the fluorescence imaging of the nano drug delivery platform in tumor-bearing nude mice;
[0037] Fig.10 This is the distribution map of the nano drug delivery platform in the main organs and tumors of tumor-bearing nude mice;
[0038] Fig.11 Photothermal imaging of the nanodrug delivery platform in tumor-bearing nude mice;
[0039] Fig.12 This is a graph showing the changes in tumor volume in tumor-bearing nude mice;
[0040] Fig.13 Figure 2 shows the weight changes of tumor-bearing nude mice. DETAILED DESCRIPTION
[0041] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0042] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0043] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0044] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0045] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0046] Example 1 Preparation of Metal Nanomaterials
[0047] The metal nanomaterial of the present invention is composed of a metal coordination center Fe(III) coordinated with a ligand 2-aminoterephthalic acid, and the specific preparation method is as follows:
[0048] FeCl3 (0.2 g) and 2-aminoterephthalic acid (0.1 g) were added to a dimethylformamide (DMF) solution (8 mL), and ultrasonicated for 30 min until completely dispersed to obtain a mixture. The obtained mixture was sealed, heated at 130 ° C for 24 h, cooled to room temperature, and the obtained solid was collected by centrifugation, repeatedly washed with DMF and methanol, and finally freeze-dried to obtain the metal nanomaterial MIL-101.
[0049] The metal nanomaterial MIL-101 particles are regular octahedrons with diameters ranging from 300 to 600 nm. The surface is distributed with micropores. The BET method calculates that the diameter of the micropores is about 3.38 nm. The specific surface area of the metal nanomaterial is 871.5889 m 2 / g, which is the basis for efficient loading and transportation of drugs.
[0050] Example 2 Hydrogen sulfide donor modification
[0051] The hydrogen sulfide donor functional group 5-(4-hydroxyphenyl)-3H-1,2-disulfide-3-thione undergoes esterification with the carboxyl group (-COOH) on the surface of the metal nanomaterial, that is, the exposed carboxyl group (-COOH) of the ligand that is not coordinated to the metal coordination center undergoes an esterification reaction with the hydroxyl group (-OH) of the functional group 5-(4-hydroxyphenyl)-3H-1,2-disulfide-3-thione, and dehydrates to form an ester bond (-COOC-). In this embodiment, the hydrogen sulfide gas donor is modified on the surface of the metal nanomaterial MIL-101 in Example 1, and the method is as follows:
[0052] 25 mg of metal nanomaterial MIL-101 was weighed and added to 15 mL of dimethylformamide (DMF) solution, and then completely dispersed by ultrasound. Then, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 66.8 mg) and triethylamine (TEA, 20 mg) were added and stirred for 1 hour, and then 40 mg of 5-(4-hydroxyphenyl)-[1,2]dithiol-3-thione (ADT-OH) was added to react for 12 hours. Finally, the solid collected by centrifugation was repeatedly washed with DMF and freeze-dried to obtain the metal nanomaterial MIL-101-ADT modified with hydrogen sulfide donor, which was used as a drug delivery platform for loading prodrug ISL. 5-(4-hydroxyphenyl)-3H-1,2-dithiol-3-thione successfully modified on the surface of metal nanomaterials can be reduced by reductase in cells to continuously release high concentrations of hydrogen sulfide gas.
[0053] Example 3 Preparation of organic compound ISL
[0054] like Figure 1 As shown in the synthetic route, the organic compound ISL is composed of a cyanine organic dye IR780 and a cell respiration inhibitor lonidamine (CAS: 50264-69-2) covalently linked by bis(2-hydroxy) disulfide to form a dimer. The specific preparation method is as follows:
[0055] IR780 iodide (250 mg, 0.37 mmol, CAS: 207399-07-3), p-hydroxybenzoic acid (103 mg, 0.75 mmol) and potassium carbonate (K2CO3, 100 mg) were dissolved in ultra-dry acetonitrile (MeCN, 25 mL), protected by nitrogen, heated to 85 ° C, and refluxed for 12 h. The reaction was detected by TLC (DCM / MeOH=10 / 1). After the reaction was completed, it was separated and purified by silica gel column chromatography (eluent DCM / MeOH=25 / 1), and evaporated under reduced pressure to obtain a solid IR780 derivative 1;
[0056] Lonidamine (120 mg, 0.37 mmol), 4-dimethylaminopyridine (DMAP, 91.3 mg) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 143 mg) were dissolved in dichloromethane (DCM, 25 mL), triethylamine was added to adjust the pH, and after stirring for 1 h, bis(2-hydroxyethyl) disulfide (90 mg, 0.58 mmol) was added, and nitrogen was protected and reacted at room temperature for 24 h. The reaction was detected by TLC (DCM / MeOH=15 / 1). After the reaction was completed, it was separated and purified by silica gel chromatography (eluent DCM / MeOH=80 / 1), and the oily Lonidamine derivative 2 was obtained after reduced pressure evaporation;
[0057] IR780 derivative 1 (200 mg, 0.31 mmol), 4-dimethylaminopyridine (DMAP, 77 mg) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 120 mg) were dissolved in ultra-dry acetonitrile (MeCN, 20 mL), triethylamine (TEA) was added to adjust the pH, and after stirring for 1 h, lonidamine derivative 2 (150 mg, 0.33 mmol) was added, and nitrogen was protected and reacted at room temperature for 24 h. The reaction was detected by TLC (DCM / MeOH=10 / 1). After the reaction was completed, it was separated and purified by silica gel chromatography (eluent DCM / MeOH=15 / 1), and the organic compound ISL was obtained after reduced pressure evaporation.
[0058] Example 4 Drug Loading
[0059] The organic compound ISL (1 mg) prepared in Example 3 was completely dissolved in dimethyl sulfoxide (DMSO, 1 mL), diluted with phosphate buffered saline (PBS) with a volume of 3 times that of DMSO (3-6 times the volume can achieve the same effect), and 10 mg of the metal nanomaterial MIL-101-ADT modified with the hydrogen sulfide donor prepared in Example 2 was added, stirred at room temperature for 8 hours, then centrifuged at 10000 r / min for 5 minutes, the precipitate was retained, and the solvent was removed by freeze drying to obtain a nano drug delivery platform loaded with the organic compound ISL. The preparation process is as follows: Figure 2 shown.
[0060] The morphology of the nano drug delivery platform is Figure 3 As shown in the figure, the particles are regular octahedrons with a diameter of 300-600nm; the specific surface area measured by the adsorption-desorption isotherm is 871.5889m 2 / g, the large specific surface area enables the nanomedicine platform to efficiently load drug molecules, such as Figure 4 As shown; the pore size distribution results are shown Figure 5 As shown in the figure, the micropore diameter calculated by the BET method is about 3.38nm. The appropriate specific surface area can load as much organic compound ISL as possible in it; the characteristic elements are found by X-ray energy dispersion spectrum, confirming that the hydrogen sulfide donor and the organic compound ISL are loaded with the nano drug delivery platform. The results are shown in Figure 6 shown.
[0061] Example 5
[0062] Tumor-bearing (H1975 cell line) nude mice were randomly divided into two groups, namely a blank group and a nanodrug delivery platform group (ISL@MIL-101-ADT+L), with 5 mice in each group, and intravenously injected with normal saline (0.2 mL) and the nanodrug delivery platform solution loaded with the organic compound ISL prepared in Example 4 (0.4 mg / mL, 0.2 mL), respectively. The drugs were injected once every two days, and the tumor was irradiated with 808 nm laser for 10 minutes 6 hours after the injection for two weeks (14 days). The body weight and tumor size of the nude mice were recorded before administration.
[0063] After the treatment, blood was collected from the eyeballs of the experimental nude mice for blood analysis, and the main organs (heart, liver, spleen, lung, kidney) and tumors of the nude mice were sectioned and stained (hematoxylin-eosin staining method). The experimental results are as follows Figure 7-8 The results showed that there was no significant difference between the nano drug delivery platform group (ISL@MIL-101-ADT+L) and the blank group, proving that the nano drug delivery platform has good biocompatibility and safety at this therapeutic concentration. Fig. 9 As shown in Figure 2, the nano drug delivery platform is distributed in major organs and tumors. Fig.10 As shown. Nude mice bearing tumor (H1975) were treated by intravenous injection, and the in vivo photothermal imaging of nude mice was shown as follows. Fig.11 The above results confirm that the nano drug delivery platform has the ability to target tumor tissues.
[0064] The nano drug delivery platform was intravenously administered once every two days. After 14 consecutive days of treatment, the tumor volume of tumor-bearing nude mice changed as follows: Fig.12 As shown in Figure 2, the body weight changes of nude mice were as follows: Fig.13 shown.
[0065] The above results confirm that this nanodrug delivery platform has a highly efficient anti-tumor effect while also having good biocompatibility and safety.
[0066] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A multifunctional visualized nano drug delivery platform, characterized in that: It comprises a metal nanomaterial, an organic drug molecule and a hydrogen sulfide donor, wherein the organic drug molecule is loaded on the surface and micropores of the metal nanomaterial, and the hydrogen sulfide donor is modified on the surface of the metal nanomaterial; The metal nanomaterial is composed of a metal coordination center trivalent Fe coordinated with a ligand 2-aminoterephthalic acid, and the metal nanomaterial is in the form of a regular octahedron; The organic drug molecule is a dimer composed of a tumor drug molecule and a tumor targeting molecule; The tumor drug molecule is Lonidamine, the tumor targeting molecule is IR780, and the structural formula of the dimer is as follows: The hydrogen sulfide donor is 5-(4-hydroxyphenyl)-3H-1,2-dithio-3-thione.
2. The multifunctional visualized nano drug delivery platform according to claim 1, characterized in that: The organic drug molecules are loaded on the surface and micropores of the metal nanomaterial through electrostatic action.
3. The multifunctional visualized nano drug delivery platform according to claim 1, characterized in that: The hydrogen sulfide donor is modified on the surface of the metal nanomaterial through covalent bonds.
4. Use of the multifunctional visualized nano drug delivery platform as described in any one of claims 1 to 3 in the preparation of tumor therapeutic drugs.
5. A tumor treatment drug, characterized in that: The invention comprises the multifunctional visualized nano drug delivery platform as described in any one of claims 1 to 3.
6. The drug according to claim 5, characterized in that The drug also includes pharmaceutically acceptable excipients.
